Evidence map›Paper›PMID 36009581›Full record

ArticleBiomedicines2022

Serum Osmolarity and Vasopressin Concentration in Acute Heart Failure-Influence on Clinical Course and Outcome.

Mateusz Guzik, Mateusz Sokolski, Magdalena Hurkacz, Agata Zdanowicz, Gracjan Iwanek, Dominik Marciniak, Robert Zymliński, Piotr Ponikowski, Jan Biegus

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mateusz GuzikInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.
Mateusz SokolskiInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.ORCID 0000-0001-9925-3566
Magdalena HurkaczDepartment of Clinical Pharmacology, Wroclaw Medical University, 50-556 Wrocław, Poland.
Agata ZdanowiczInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.
Gracjan IwanekInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.ORCID 0000-0002-8574-9963
Dominik MarciniakDepartment of Drugs Form Technology, Wroclaw Medical University, 50-556 Wrocław, Poland.
Robert ZymlińskiInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.ORCID 0000-0003-1483-7381
Piotr PonikowskiInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.
Jan BiegusInstitute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland.ORCID 0000-0001-9977-7722
Wroclaw Medical University · PL

Funding

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland SUBZ.A460.22.055
6 · The paper itself

Abstract

Neurohormone activation plays an important role in Acute Heart Failure (AHF) pathophysiology. Serum osmolarity can affect this activation causing vasopressin excretion. The role of serum osmolarity and vasopressin concentration and its interaction remain still unexplored in AHF. The objective of our study was to evaluate the relationship of serum osmolarity with clinical parameters, vasopressin concentration, in-hospital course, and outcomes in AHF patients. The study group consisted of 338 AHF patients (male (76.3%), mean age of 68 ± 13 years) with serum osmolarity calculated by the equation: 1.86 × sodium [mmol/L] + (glucose [mg/dL]/18) + (urea [mg/dL]/2.8) + 9 and divided into osmolarity quartiles marked as: low: <287 mOsm/L, intermediate low: 287−294 mOsm/L, intermediate high: 295−304 mOsm/L, and high: >304 mOsm/L. There was an increasing age gradient in the groups and patients differed in the occurrence of comorbidities and baseline clinical and laboratory parameters. Importantly, analysis revealed that vasopressin presented a linear correlation with osmolarity (r = −0.221, p = 0.003) and its concentration decreased with quartiles (61.6 [44.0−81.0] vs. 57.8 [50.0−77.3] vs. 52.7 [43.1−69.2] vs. 45.0 [30.7−60.7] pg/mL, respectively, p = 0.034). This association across quartiles was observed among de novo AHF (63.6 [55.3−94.5] vs. 58.0 [50.7−78.6] vs. 52.0 [46.0−58.0] vs. 38.0 [27.0−57.0] pg/mL, respectively, p = 0.022) and was not statistically significant in patients with acute decompensated heart failure (ADHF) (59.5 [37.4−80.0] vs. 52.0 [38.0−74.5] vs. 57.0 [38.0−79.0] vs. 50.0 [33.0−84.0] pg/mL, respectively, p = 0.849). The worsening of renal function episodes were more frequent in quartiles with higher osmolarity (4 vs. 2 vs. 13 vs. 11%, respectively, p = 0.018) and patients that belonged to the quartiles with low and high osmolarity were characterized more often by incidence of worsening heart failure (20 vs. 9 vs. 10 vs. 22%, respectively, p = 0.032). There was also a U-shape distribution in relation to one-year mortality (31 vs. 19 vs. 23 vs. 37%, respectively, p = 0.022). In conclusion, there was an association of serum osmolarity with clinical status and both in-hospital and out-of-hospital outcomes. Moreover, the linear dependence between vasopressin concentration and serum osmolarity in the AHF population was identified and was driven mainly by patients with de novo AHF which suggests different pathophysiological paths in ADHF and AHF de novo.

Indexed as

acute heart failureosmolarityoutcomesvasopressin

Identifiers

PMID36009581
PMCPMC9405797
OpenAlexW4292548929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.